文献速递慢性肾脏病水电解质与酸碱

新型钾结合剂能否解放CKD患者免于低钾饮食?一个警示性故事

Can Novel Potassium Binders Liberate People with Chronic Kidney Disease from the Low-Potassium Diet? A Cautionary Tale.
PubMed 文献 · Clin J Am Soc Nephrol · 2021-10-20

本文综述新型钾结合剂在CKD高钾血症管理中的作用机制,指出这些药物主要作用于大肠,而膳食钾限制的主要证据针对餐后高钾血症。尽管钾结合剂能有效降低基础钾水平,但其是否能预防过量膳食钾摄入所致高钾血症尚不明确。在明确之前,临床医生在解除CKD患者膳食钾限制时应考虑餐后高钾血症风险。

要点

  • 钾结合剂主要作用于大肠,而膳食钾吸收主要在小肠。
  • 膳食钾限制的主要证据针对餐后高钾血症,而非钾生物累积。
  • 钾结合剂能否预防膳食钾所致高钾血症尚不明确。

核心结论

  • 尽管钾结合剂能有效降低基础钾水平,但其是否预防膳食钾所致高钾血症尚不明确。
  • 临床医生在解除CKD患者膳食钾限制时应考虑餐后高钾血症风险。

研究设计与样本

  • 本文为综述,未报告系统检索范围或样本量。

主要发现

  • 钾结合剂主要作用于大肠,而大部分摄入钾在小肠吸收。
  • 膳食钾限制的主要证据针对餐后高钾血症风险。
  • 钾结合剂降低基础钾水平有效,但对膳食钾所致高钾血症的保护作用不确定。

临床怎么用

  • 在CKD患者使用钾结合剂时,解除膳食钾限制前应评估餐后高钾血症风险。

局限性

  • 钾结合剂对膳食钾所致高钾血症的保护作用尚不明确,需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The advent of new potassium binders provides an important breakthrough in the chronic management of hyperkalemia for people with CKD. In addition to the direct benefits of managing hyperkalemia, many researchers and clinicians view these new medications as a possible means to safely transition patients away from the low-potassium diet to a more healthful eating pattern. In this review, we examine the mechanisms of potassium binders in the context of hyperkalemia risk related to dietary potassium intake in people with CKD. We note that whereas these medications target hyperkalemia caused by potassium bioaccumulation, the primary evidence for restricting dietary potassium is risk of postprandial hyperkalemia. The majority of ingested potassium is absorbed alongside endogenously secreted potassium in the small intestines, but the action of these novel medications is predominantly constrained to the large intestine. As a result and despite their effectiveness in lowering basal potassium levels, it remains unclear whether potassium binders would provide protection against hyperkalemia caused by excessive dietary potassium intake in people with CKD. Until this knowledge gap is bridged, clinicians should consider postprandial hyperkalemia risk when removing restrictions on dietary potassium intake in people with CKD on potassium binders.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. St-Jules DE, Clegg DJ, Palmer BF, et al. Can Novel Potassium Binders Liberate People with Chronic Kidney Disease from the Low-Potassium Diet? A Cautionary Tale. Clin J Am Soc Nephrol. 2021. PMID: 34670798. doi:10.2215/CJN.09660721

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。